Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients

NCT01134250 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Breast Cancer
Metastatic Melanoma
Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: F16IL2 in combination with paclitaxel

Sponsor

Philogen S.p.A.